Capsulas
Welcome to CAPSULAS, our newsletter in which, since 1997, we have been informing clients and friends about novelties of interest in the area of pharmaceutical law in Spain and in the European Union.
Transfers of personal data to the US in research studies conducted in Spain
Frequently Asked Questions on the EU-US Data Privacy Framework document issued by the European Data Protection Board on 16 July 2024
Pablo Mansilla
Capsulas Nº 257
EU Ecolabel only if products comply with EU requirements
Judgment of the Court of 4 October 2024, Herbaria Kräuterparadies, C-240/23
Laia Rull
Capsulas Nº 257
What news may we expect in Spain’s pharmaceutical policy in the next few months?
Some notes on the intervention of the Secretary of State for Health in Congress on October 14
Joan Carles Bailach, Jordi Faus
Capsulas Nº 256
The Supreme Court confirms that companies have locus standi to challenge the marketing authorisation granted to a competitor
Judgments of the Supreme Court, Nos. 827/2024 and 1241/2024, of 14 May and 10 July
Jordi Faus, Juan Martínez and Joan Carles Bailach
Capsulas Nº 255
Progress in the regulation of health technology assessment
The Ministry publishes the Draft Royal Decree, and the deadline for submitting allegations is 20 September
Lluís Alcover
Capsulas Nº 254
Which aspects of personal data protection should be included in the patient information sheet and informed consent form?
Report of the Legal Department of the Spanish Data Protection Agency (AEPD) of 12 March 2024
Eduard Rodellar and Pablo Mansilla
Capsulas Nº 254
Loss of opportunity is compensable in public procurement
Judgment of the Court of Justice of the European Union of 6 June 2024 (C-547/22)
Xavier Moliner and Claudia Gonzalo